Document Detail


A double-blind controlled trial of a single dose naproxen and an amino Acid medical food theramine for the treatment of low back pain.
MedLine Citation:
PMID:  20861716     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
To study the safety and efficacy of a new medical food (Theramine) in the treatment of low back pain, we performed a 28-day double-blind randomized controlled trial in 129 patients. Back pain was present for at least 6 weeks and was not mild. Patients were randomly assigned to receive medical food alone (n = 43), naproxen alone (250 mg/d, n = 42), or both medical food and naproxen (n = 44). All patients were assessed by using Roland-Morris Disability Questionnaire, Oswestry Low Back Pain Scale, Visual Analog Scale Evaluation and laboratory analysis performed at baseline and at 28 days for assessing the safety and impact on inflammatory markers, which included complete blood counts, C-Reactive protein (CRP), and liver function (alkaline phosphatase, aspartate transaminase, and alanine transaminase). At baseline, there were no statistically significant differences in low back pain when assessed by Roland-Morris function or Oswestry assessments nor were there differences in the blood indices of inflammation. At day 28, both the medical food group and combined therapy group (medical food with naproxen) were statistically significantly superior to the naproxen-alone group (P < 0.05). The medical food and naproxen group showed functional improvement when compared to the naproxen-alone group. The naproxen-alone group showed significant elevations in CRP, alanine transaminase, and aspartate transaminase when compared with the other groups. Medical food alone or with naproxen showed no significant change in liver function tests or CRP, with medical food potentially mitigating the effects seen with naproxen alone. The medical food (Theramine) appeared to be effective in relieving back pain without causing any significant side effects and may provide a safe alternative to presently available therapies.
Authors:
William E Shell; Elizabeth H Charuvastra; Marcus A Dewood; Lawrence A May; Debora H Bullias; David S Silver
Related Documents :
22266286 - Cognitive and neuronal systems underlying obesity.
15016566 - Investigation of the importance of the c-2 oxygen function in the transformation of ste...
22976736 - Nutritional practices of elite swimmers during an intensified training camp: with parti...
24348176 - Effect of supplementation with antioxidants on the quality of bovine milk and meat prod...
24925656 - Dissociation of instrumental and pavlovian contingencies in a discriminated instrumenta...
7691536 - Presentation of a general algorithm to include effect assessment on secondary poisoning...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of therapeutics     Volume:  19     ISSN:  1536-3686     ISO Abbreviation:  Am J Ther     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-03-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  108-14     Citation Subset:  IM    
Affiliation:
1Physician Therapeutics, Los Angeles, CA 2UCLA School of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rhinocerebral mucormycosis complicated by bacterial brain abscess.
Next Document:  Treatment of stable angina pectoris.